retatrutide dosage trial Triple hormone receptor agonist for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a Retatrutide just posted the biggest

In this blog post, we aim to equip you with practical strategies to alleviate nausea associated with GLP-1 medications, exploring dietary adjustments, lifestyle changes, and when to seek professional help

"Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA." The Lancet

Interestingly, the medications that may be the most effective at achieving the desired outcome can be the ones that are more likely to cause adverse effects

But weight loss isnt just fat loss

Retatrutide and other triple agonists are fully synthetic compounds designed to engage multiple receptors simultaneously

It is unknown exactly who will be able to receive a retatrutide prescription this will only be determined when the FDA approves the drug